Yellow Fever, an Arboviral Disease with Public Health Impacts: General Aspects and the Use of the One Health Approach in the Context of This Zoonosis Authors: Larissa de Souza Araújo, Igor Rosa Meurer Published: 2026 ABSTRACT AbstractYellow fever is a long-standing zoonotic arboviral disease that affects hundreds of thousands of people annually in different regions of the world, even though the vaccine has been available since the 1930s. Thus, studies that synthesize general and current information on yellow fever are relevant, aiming to disseminate knowledge that can contribute to mitigating its impacts. This narrative review synthesizes the general aspects of yellow fever, discusses its impacts on public health, and presents information on the use of the One Health approach in the context of this zoonosis. The databases used to select the articles were PubMed, Scopus, LILACS, and SciELO, using various descriptors related to the study’s theme and objectives. It is important to highlight that yellow fever remains a significant public health challenge due to its high mortality rate in severe cases and the continued circulation of the yellow fever virus in tropical areas, especially in South America and Africa. Although many patients recover spontaneously, recurrent outbreaks continue in endemic regions. The initial clinical similarity to other zoonoses makes timely diagnosis difficult, and management remains restricted to clinical support, as there is no specific antiviral treatment. Vaccination and epidemiological surveillance stand out as the main preventive measures. Additionally, considering that the management of yellow fever involves human, animal, and environmental health aspects, the One Health approach stands out as a modern, robust, and effective alternative for addressing this zoonosis. However, the lack of knowledge regarding this approach among public managers and health professionals results in its non-use and, consequently, impacts the fight against yellow fever. Therefore, it is important to widely disseminate knowledge about the One Health approach, aiming at carrying out holistic actions in the human-animal-environmental interface sectors in the context of yellow fever, allowing for coordinated and sustainable responses at different levels and instances. Introduction Yellow fever (YF) is an arboviral disease with a high impact on public health globally, especially in tropical countries of Africa and Latin America.1–4 The disease is transmitted by female hematophagous mosquitoes infected with the yellow fever virus (YFV), belonging to the genus Flavivirus, of the family Flaviviridae.5,6 Clinical manifestations vary according to the form of presentation: mild, moderate, or severe. Cases can be asymptomatic or symptomatic, with initially nonspecific signs and symptoms similar to the classic clinical presentations of viral syndromes, which makes diagnosis difficult. However, as the disease progresses, in moderate and severe cases, the severity increases, and hepatic and renal alterations, coagulopathies, and high fever may be present.4,7 Although most human infections are asymptomatic or present as mild forms with low morbidity, severe cases can progress to high fatality, exacerbated by the difficulty of early disease recognition and the lack of specific treatment, reaching rates between 40% and 60% in South America and around 20% in Africa. Similarly, infection in non-human primates (NHPs), especially Neotropical species in South America, frequently results in epizootics with high mortality, making these animals important sentinels for viral circulation. In this context, vaccination and epidemiological and sanitary surveillance in humans and NHPs, combined with timely diagnosis, constitute the primary strategies for the prevention and control of yellow fever.8–13 This is of paramount importance, considering the number of human outbreaks recorded in recent years, which affected more than 15 African countries between 2020 and 2021 alone, significantly impacting public health. The origin of these occurrences is multiple, being strongly associated with the spillover of the yellow fever virus in non-human primates and low vaccination coverage.2,14,15 The availability of a highly effective vaccine, yellow fever remains a significant challenge today due to persistent outbreaks, primarily associated with insufficient vaccination coverage, inequities in access to immunization, and the persistence of the sylvatic transmission cycle.2,14,16 In recent decades, the disease has expanded geographically across South America, particularly in Brazil, with cases spreading to densely populated areas that were previously non-endemic; this has raised concerns regarding the potential for the re-urbanization of viral transmission in regions with susceptible populations.3,4,17,18 Furthermore, environmental changes, such as deforestation, climate change, and land-use modifications, facilitate the circulation of the virus and expand the interface between humans, NHP and vectors, highlighting the cross-sectoral nature of yellow fever management.3,19 Considering the complexity of managing yellow fever, which involves aspects of human health, animal health, and environmental health, the One Health approach is seen as an effective alternative for tackling this zoonosis.20–22 However, many professionals remain unaware of this approach, making its widespread disclosure necessary.23 In light of the foregoing, it is evident that yellow fever remains a significant global public health issue and that governmental, technical, and scientific actions are required to reverse this situation. In this context, it is essential to publish articles that provide a concise overview of current information on yellow fever, thereby contributing to the dissemination of knowledge among the stakeholders responsible for addressing this zoonosis. This narrative review synthesizes information on the general aspects of yellow fever, including the characteristics of the etiological agent and its pathogenesis, the main clinical manifestations, the modes of transmission of the disease, the means of treatment and prevention, diagnostic tools, and epidemiological data. Furthermore, it discusses the impacts of yellow fever on public health and presents relevant and current information on the use of the One Health approach in the context of this zoonosis. Etiological Agent and Pathogenesis In 1900, physician Walter Reed and his commission, through experiments, demonstrated that the etiological agent was a virus, which was isolated a few years later, in 1927, from the serum of rhesus monkeys by Adrian Stokes and his team during outbreaks in Africa.2,24 The yellow fever virus is the prototype of the Flaviviridae family, belonging to the Flavivirus genus. The name “Flaviviridae” originates from the Latin language, where it means “yellow”, in reference to the jaundice that the disease can cause.5,6,25 The YFV is a spherical, enveloped virus approximately 50 nm in diameter, with an average of 11 kb of nucleotides, possessing a single-stranded, non-segmented, positive-sense RNA genome. Thus, its genome functions as a large mRNA, translated into a single long polyprotein, subsequently cleaved co- and post-translationally into ten viral proteins: three structural proteins [Core, PrM (pre-membrane), and E (envelope)] and seven non-structural proteins (NS; NS1, NS2A-2B, NS3, NS4A-B, and NS5).26–28 The yellow fever virus binds to heparan sulfate on the cell surface to initiate infection and release its genome into the cytoplasm. After translation of the polyprotein and formation of the replication complex, viral RNA replication occurs. In the assembly stage, nucleocapsids, composed of core proteins and viral RNA, are enveloped by endoplasmic reticulum membranes, giving rise to immature virions with PrM-E proteins in the envelope, organized into structures that house capsid dimers (Core) associated with viral RNA. These then proceed to the Golgi complex, where cleavage of the PrM protein promotes viral maturation and release. The virus can also alter other cellular organelles, such as mitochondria, lipid droplets, and autophagosomes.5,26,29,30 After transmission of the YFV to the host, the virus infects antigen-presenting cells, especially dendritic cells, which migrate to the lymph nodes to present the antigen to T lymphocytes. In this same location, the YFV amplifies and prepares for a cellular immune response before disseminating to different organs via the peripheral blood, including the liver and, in some cases, the heart, thymus, kidney, and spleen.28 Upon reaching the liver tissue, the yellow fever virus induces hepatocyte apoptosis and necrosis, causing significant liver damage and systemic complications.31 Beyond the direct hepatic issue, the exacerbated systemic immune response, with uncontrolled activation of cytokines, is a central aspect in this process of liver damage. Converging with this, Th1 and Th3 helper T cells can be observed in this tissue; therefore, pro-inflammatory cytokines derived from these cell types are present, such as tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), important mediators of liver injury, as well as tumor necrosis factor beta (TGF-β), which is pro-apoptotic.28,32,33 It is worth mentioning that the intrinsic aspects and precise mechanisms of YFV pathogenesis are not fully elucidated, especially due to the scarcity of animal models that recapitulate the human characteristics of this process. In general, current knowledge is based on biopsies from fatal cases, studies in animal models, and transcriptomic and cellular analyses, generally focusing on mononuclear cells and the YFV-17D vaccine strain.28,33 The YFV genome generally exhibits neutral or purifying selection, although it may present mutations and genetic variability that allow for its analysis and classification, for example, according to geographic origin. There are four main genotypes (East African, West African, South American I and II), in addition to subclasses with lower incidence. Although they do not have a significant clinical impact, these variations are relevant for epidemiological surveillance.19,34,35 Clinical Manifestations Yellow fever is a disease with clinical manifestations that can vary from signs and symptoms of a mild and nonspecific viral syndrome to severe cases, with liver failure, coagulopathies, and death.4 In general, yellow fever is divided into three phases: infection, remission, and toxic phase, although not all infected individuals complete this cycle.36 This occurs because yellow fever can present in mild, moderate, or severe forms.7 The manifestation is mild in about 80% of cases, presenting itself in those who have acquired antibodies passively or actively; while in those who have immunity to other flaviviruses, the signs and symptoms may be moderate. Severe disease, for example, can be observed in immunocompromised individuals and/or those with sub-neutralizing antibodies due to cross-immunity from secondary flavivirus infection, due to the antibody-dependent enhancement (ADE) phenomenon.37–39 In a broad analysis, it is observed that from the initial contact with the YFV, there is a viral incubation period of 3 to 6 days and, subsequently, flu-like symptoms suddenly appear, such as myalgia, headache, loss of appetite, nausea, vomiting, and high fever with measured temperatures of up to 41°C in adults.31,40 Subsequently, the disease goes into remission, causing a feeling of improvement in the infected person, with a decrease in temperature and intensity of symptoms, for about hours to a maximum of two days. However, on average 24 hours after this period, some individuals (20–60%) relapse and progress to the toxic phase, the most severe of the disease, with a return of high fever and the possibility of involvement of various organs, especially the liver, with the infected person possibly presenting hepatomegaly, as this is the site where active viral replication occurs, due to it being a phase with viscerotropic characteristics.31 The toxic phase is marked by the return of fever, pain, nausea, and more intense vomiting, and may be accompanied by renal dysfunction with oliguria, hypotension, severe hemorrhages with internal and external bleeding, petechiae and ecchymoses, as well as pulse-temperature dissociation (Faget’s sign) and liver damage, leading to jaundice, the manifestation from which the disease derives its name.2,40 In the clinical presentation of this more severe stage, bacterial and fungal sepsis, encephalitis, encephalopathy, meningitis, and hemophagocytic lymphohistiocytosis can still be observed in neurotropic cases. The toxic phase of yellow fever has a rapid worsening, with death occurring between 7 and 14 days, varying between 20 and 50% of those affected, in most cases due to fulminant hepatic failure.25 It is important to mention that there are also asymptomatic cases, with the average ratio of symptomatic to asymptomatic infection of YF being 1:7–12. Specifically, of the infections that have clinical manifestations, 73% are mild or moderate and 27% are severe.2,4 However, even among symptomatic cases, yellow fever may be underreported, especially in mild forms, due to nonspecific signs and symptoms, often similar to those of other arboviruses. Transmission The yellow fever virus is transmitted through infected arthropods of the Culicidae family, commonly known as mosquitoes, traditionally endemic to tropical regions of Africa and South America. Transmission occurs only through infected females, who then carry the virus through vertical transmission to their offspring or by biting infected hosts that are in the viremic period.41 The YFV presents three transmission cycles: the sylvatic (or enzootic), the intermediate (or savanna), and the urban (or domestic). The urban cycle, with humans as hosts and Aedes aegypti as the vector, is still relevant in some locations in Africa, but is extinct in countries like Brazil. Unlike the urban cycle, the sylvatic cycle is not susceptible to control, exposing populations in endemic areas to sporadic epizootics. The intermediate cycle involves transmission between non-human primates and semi-domesticated mosquitoes (Aedes spp)., with humans as accidental hosts, mainly affecting those who live and/or work near African savannas.4,31,41 The sylvatic cycle primarily involves Sabethes spp. and Haemagogus spp. as vectors, with NHPs as primary hosts and humans as accidental hosts. Despite some similarities between these vectors, such as diurnal habits and the restriction of being sylvatic, Sabethes spp. and Haemagogus spp. have distinct features, such as their visual characteristics and the fact that Haemagogus spp. is not restricted to robust vegetation, being found on the periphery of forests and reaching areas with human activity more easily.10,42–44 Among the species of the genus Haemagogus, Hg. janthinomys and Hg. leucocelaenus stand out, exhibiting significant ecological differences. Hg. leucocelaenus moves more frequently between the upper and lower forest strata, is predominantly diurnal in its blood-feeding activity, and is better adapted to cold climates, explaining its presence in southern Brazil, unlike Hg. janthinomys, which is strongly acrodendrophilic. Furthermore, Hg. leucocelaenus is frequently found in forest fragments near areas of human activity, including agricultural lands, pastures, riverbanks, and urban green spaces.10,43 In the sylvatic cycle, South American NHPs are essential for monitoring YF because they are highly susceptible and have high mortality rates, acting as epidemiological sentinels. In contrast, African primates have low lethality and are not used for this purpose.9,10,44 A rare form of yellow fever transmission occurs in newborns through breastfeeding by recently vaccinated mothers because the vaccine contains an attenuated virus. From this perspective, yellow fever vaccination in pregnant women becomes a risk factor due to the possible severe progression, such as encephalopathy. Therefore, it is recommended to interrupt breastfeeding for 10 days after inadvertent vaccination in lactating women.36,45 Treatment Currently, there is no specific treatment for yellow fever, only supportive measures using analgesics and antipyretics, when necessary. Thus, the signs and symptoms of the disease are managed according to the clinical manifestations.31,46 In general, outpatient follow-up is sufficient for mild and moderate cases, most of which are self-limiting. Even so, oral hydration (60 mL/kg/day) is recommended, adjusted to tolerance; in cases where oral administration is not possible, intravenous replacement with 30 mL/kg/day of crystalloids (0.9% saline solution or Ringer’s lactate) is indicated. For symptomatic patients with fever, it is recommended to monitor hemostasis and liver and kidney function, with transaminase and creatinine levels, as well as a complete blood count and INR every 24 hours, continuing for up to 48 hours after fever remission.44,47,48 In moderate cases, hospital admission with maintenance of hydration is indicated. In cases of dehydration, hypotension, and oliguria, volume expansion of 20 mL/kg/h is recommended, with hemodynamic and urinary reassessment after the first hour and then every 12 hours, in addition to clinical evaluation every 4 hours. Investigations for hemorrhages and the need for transfusions should also be carried out.44,47,48 In severe cases, management in an intensive care unit (ICU) is recommended from the initial assessment due to the high risk of complications.46 At this stage, rigorous monitoring of temperature, diuresis, volemia, fluid balance, acid-base balance, and vital signs should be maintained.44,47,48 Furthermore, secondary infections and hemorrhages should be investigated, avoiding nonsteroidal anti-inflammatory drugs (NSAIDs) as they inhibit platelet aggregation and increase the risk of bleeding and acidosis, and should be discontinued even in chronic use. Paracetamol is also not recommended at this stage, although it can be used in mild and moderate forms at doses up to 3 g/day.49 Although current treatment is nonspecific, some studies investigate personalized therapy for yellow fever. Rezende et al demonstrated the efficacy of off-label use of Sofosbuvir 400 mg/day in a retrospective cohort study with patients hospitalized during a yellow fever outbreak in Brazil in 2018. The study analyzed three groups: untreated patients who survived (n = 39), untreated patients who died (n = 7), and patients treated with Sofosbuvir (n = 21). It concluded that individuals who received the medication showed a reduction in viral load and faster improvement in biochemical markers, approximately seven days after the onset of symptoms.50 Sofosbuvir is a direct-acting antiviral against the hepatitis C virus, with promising results in in vitro, in vivo (in animal models) and off-label studies, demonstrating a reduction in viremia and efficacy, especially when administered early, although it also shows benefits in later stages. However, its clinical use for yellow fever is not yet approved due to the lack of robust studies in humans.51,52 Furthermore, in 2023, synthetic monoclonal antibodies tested in rhesus monkeys and hamsters demonstrated efficacy in neutralizing YFV, with a reduction in infection and mortality. However, like Sofosbuvir, its clinical use still requires human trials to prove safety and efficacy.53 Given the information presented, it is important to emphasize that the management of yellow fever remains limited to supportive measures and clinical monitoring, due to the absence of a specific approved treatment. Although recent investigations involving Sofosbuvir and synthetic monoclonal antibodies show promising results in animal models and retrospective studies, current scientific evidence is preliminary. Given the scarcity of robust clinical trials in humans, such therapies are strictly experimental in nature and lack recommendations for routine use in clinical practice. Control and Prevention Yellow fever is vaccine-preventable, with vaccination being the main control measure. Developed in the 1930s from the 17D strain, the vaccine uses live attenuated virus, capable of inducing an immune response similar to natural infection, but milder, guaranteeing humoral, cellular, and memory immunity. Current vaccines are derived from this strain and maintain the same principle.14,31,54 Although widely available, the vaccine is prioritized for individuals in endemic areas and travelers to at-risk regions, aiming to prevent the national and international spread of the virus. In these cases, the International Certificate of Vaccination or Prophylaxis (ICVP) may be required at ports, airports, and borders.2,55,56 African and South American countries frequently require travelers to present proof of vaccination before entering the country. Immunization must occur at least 10 days prior to travel, based on the fact that 90% of those vaccinated develop neutralizing antibodies within this period and 99% within 30 days. However, vaccination is contraindicated in some groups due to the risk of an exaggerated response to the attenuated virus, including pregnant women, breastfeeding women, immunocompromised individuals, children under six months of age, individuals with a history of reactions to vaccine components, those undergoing chemotherapy or radiotherapy, and transplant recipients.2,7,57 Despite widespread availability, vaccination coverage remains below the 80% target recommended by the World Health Organization (WHO) for outbreak control. This is due to structural failures in health systems, such as unequal access, irregular supply of immunobiologicals, and regional heterogeneity, in addition to sociocultural factors that influence adherence.2,14,16 In addition to vaccination, individual measures also contribute to controlling the transmission of the yellow fever virus. Simple body protection measures – chemical (repellents) and physical (clothing with greater coverage) – are recommended, especially in endemic areas. However, ordinary clothing does not guarantee complete protection against bites, and the combined use of repellents is recommended.58,59 In environmental management, it is recommended to eliminate breeding sites, apply larvicides, ensure adequate sanitation, and carry out insecticide spraying, especially in areas near forests. Isolating the patient during the viremic period, using physical barriers, also helps to interrupt transmission.60,61 However, vector control is limited in the sylvatic cycle due to the difficulty of accessing forest environments, making physical barriers insufficient to interrupt this chain of transmission.3,62 In this context, epidemiological surveillance, including epizootics in NHP, entomological and environmental surveillance, is essential to guide vaccination campaigns and prevent outbreaks, associated with laboratory diagnosis and comprehensive health care.12,13 It is important to highlight that yellow fever control does not depend on vaccine efficacy, but rather on overcoming structural barriers that keep coverage below the WHO 80% target. This immunological vulnerability, combined with the clinical restrictions of the immunobiological agent and the infeasibility of vector control within the sylvatic cycle, redefines the role of prevention. Therefore, active epidemiological surveillance, focused on the early monitoring of epizootics in primates, establishes itself as an indispensable sentinel tool for anticipating viral circulation and guiding vaccination-based containment measures, thereby mitigating the risk of human outbreaks. Main Diagnostic Tools The diagnosis of yellow fever is based on clinical and laboratory evaluation, especially in the early stages, when symptoms resemble those of other viral infections. Consideration is given to signs and symptoms, physical examination, history of travel to endemic areas, vaccination status, possible exposure to vectors, and the time since symptom onset, which guides the choice of laboratory tests.7,25,31 The gold-standard diagnostic method combines clinical evaluation with laboratory confirmation, generally using serum or plasma, analyzed by Polymerase Chain Reaction (PCR) or Plaque Reduction Neutralization Test (PRNT), depending on the stage of the disease.40,63–65 Detection by PCR, especially RT-PCR and RT-qPCR, has high sensitivity and specificity, being indicated in the acute phase, during the viremic period, usually up to the fifth day after the onset of symptoms, in whole blood, serum, or plasma samples.7 In convalescents, viral RNA can be detected, less frequently, in urine (up to 25 days) and semen (up to 20 days).25,66 PCR allows phylogenetic analysis and has advantages such as wide availability, low cost, reliable quantification, and standardization; although it can generate false positives in samples with low viral load.67,68 After the viremic period, with seroconversion, tests for the detection of anti-FAV IgM and IgG antibodies become the gold standard. The PRNT test is considered the gold standard for quantifying neutralizing antibodies, as it has better performance, especially in terms of specificity, compared to other tests, such as the Enzyme-Linked Immunosorbent Assay (ELISA), which may exhibit cross-reactions with other flaviviruses. This limitation stems from the high structural and antigenic homology among flaviviruses, which favors the production of both species-specific and cross-reactive antibodies following infection or vaccination. This phenomenon is particularly relevant in regions where multiple flaviviruses co-circulate, such as South America and Africa, where dengue, Zika, yellow fever, and other flaviviruses coexist in various combinations; in these settings, prior infections or vaccinations against other flaviviruses can reduce the specificity of serological assays and complicate the interpretation of results.7,65,69–73 However, PRNT is laborious and time-consuming (approximately one week), performed on cell cultures, generally in plates with few wells, which allows for more precise titrations but limits reproducibility. Due to its greater speed and lower cost, ELISA and MAC-ELISA diagnostics are the tests normally used routinely for laboratory screening in the non-viremic stage, with PRNT being used in cases with suspected cross-reactivity.25,63,65,69–71 Nonspecific laboratory findings also aid in clinical evaluation. Throughout the course of the disease, leukopenia with relative neutropenia, thrombocytopenia, and increased prothrombin time may occur, progressing, in severe cases, to disseminated intravascular coagulation. With progression, there is an elevation of bilirubin and transaminases, with a predominance of AST over ALT, especially in unfavorable prognoses.40,66,74 Post-mortem diagnosis can be performed by immunohistochemistry, preferably up to 24 hours after death. Samples of target organs, such as liver, spleen, lymph nodes, and myocardium, are used, collected in a sterile manner, fixed in formalin, and processed for histological analysis, with staining by specific antibodies that allow the detection of the viral antigen.7,25,40,63,75 Epidemiology The yellow fever virus has a wide geographic distribution, although it has a restricted reach and variable incidence. This heterogeneity is related to ecological, socioeconomic, and demographic factors that condition the maintenance of the vector and its activity, which explains both the seasonality and the predominance in certain regions.24 YFV has a single known serotype and is classified into four main genotypes (EAfr, WAfr, SAMI, and SAMII) and their subgroups, differing by approximately 9%. Despite these variations, there is no evidence of restricted susceptibility to infection based on ethnicity, sex, or race.19,34,35 Although there are no records of autochthonous transmission of yellow fever in Oceania and Asia, there are reports of imported Asian cases from travelers coming from endemic areas. Hypotheses for the low prevalence of the virus in these regions include the geographical variation of strains and vectors. In Asia, it is also considered that the high seroprevalence of dengue may generate cross-immunity or competition between flaviviruses in the vector.2,76–78 In 2016, China reported its first imported cases of yellow fever, linked to an outbreak in Angola. Eleven unvaccinated travelers who had been in the African country for work were identified, despite vaccination against the disease being mandatory. The episode generated concern, given that China has a wide distribution of Aedes aegypti. However, the spread did not occur due to unfavorable climatic conditions and the rapid adoption of contingency measures.14,77–79 Historically, Europe recorded outbreaks of yellow fever in the 19th century, especially on the Atlantic coast, in countries such as France, Wales, and Spain, with approximately 1200 documented deaths in Barcelona, associated with ships from the Caribbean. Currently, the occurrence of cases is low, generally limited to unvaccinated travelers returning from endemic regions. In the Netherlands, for example, there was one case in 2017 (imported from Suriname) and another in 2018 (imported from Brazil), both isolated; during the same period, France, Romania, and Switzerland also recorded one imported case each.3,11,18,80 Conversely, in both absolute and proportional numbers, African and South American countries show a higher incidence of cases, reflecting the genesis of the virus’s spread. It is considered that the YFV originated in Africa and reached the Americas through the transatlantic slave trade from endemic areas. This process was potentiated by transovarian transmission of the virus, the resistance of Aedes aegypti eggs to desiccation, and similar climatic conditions, favoring documented outbreaks since the 17th century in the New World.2,3,14,24 The current epidemiological landscape indicates that Africa accounts for the majority of yellow fever epidemics, with a greater impact than that observed in the Americas. It is estimated that the disease causes approximately 200,000 infections and 30,000 deaths annually globally, with about 90% of these cases occurring in Africa. In recent decades, however, mortality has decreased, reflecting vaccination, prior exposure to the virus, and better understanding of the vector’s periodicity in endemic areas. Despite this, this number remains underestimated compared to data released by the WHO, due to the high number of asymptomatic or mild cases and reporting failures.2,3,11,17,81 The high prevalence of cases in Africa is also associated with the presence of the intermediate cycle (savannah) in some regions of that continent, in addition to the classic, sylvatic, and urban cycles. In all cycles present on this continent, in addition to the standard vectors, YFV can be transmitted by Aedes africanus and Aedes albopictus.4 In the Americas, the Caribbean was the first region affected, with occurrences since 1647 in Barbados; subsequently, the disease expanded to South and North America. In the United States, densely populated cities on the east coast experienced intense outbreaks around 1650 and 1900, causing hundreds of thousands of deaths. The transmission of the virus was controlled in the early 20th century, similarly to what occurred in Europe.2–4 The resurgence of yellow fever in the Americas is linked to a combination of ecological and anthropogenic factors. Environmental changes resulting from deforestation, forest fragmentation, agricultural expansion, and urbanization alter the distribution of vectors and wild hosts, thereby expanding the interface between humans, non-human primates, and mosquitoes. Furthermore, the spread of the virus into previously unaffected areas, combined with low vaccination coverage among susceptible populations, has fostered the occurrence of epizootics and human outbreaks, particularly in Brazil’s Southeast and South regions, where the disease has advanced into densely populated areas previously considered low-risk.82 According to an update from the WHO, between December 2024 and April 2025, 212 cases of yellow fever were confirmed in the Region of the Americas, resulting in 82 deaths, distributed across five countries: Bolivia, Brazil, Colombia, Ecuador, and Peru. This number represents a threefold increase in the number of cases compared to the 61 confirmed in 2024, driven by the increase in sylvatic transmission cycles.83,84 In the first four months of 2025 alone, the following cases were confirmed: Bolivia, with two cases and one death; Colombia, with 53 cases and 21 deaths; and Peru, with 32 cases and 11 fatalities.84 These figures were surpassed when analyzing the 53 epidemiological weeks of 2025, during which 346 confirmed human cases were reported in the South America, including 143 deaths (case fatality rate [CFR] of 41%), representing a 5.6-fold increase compared to the previous year. These data cover Bolivia, Brazil, Colombia, Ecuador, Guyana, Peru, and Venezuela; notably, Brazil and Colombia each recorded more than 115 cases and 40 deaths. In the first seven epidemiological weeks of 2026, 34 confirmed human cases and 15 deaths (CFR: 44%) were recorded across Bolivia, Colombia, Peru, and Venezuela, marking a decrease compared to the same period of the previous year.72 Refer to Table 1. Table 1Epidemiological Information on Confirmed and Fatal Cases of Yellow Fever in Countries Located in the Region of the AmericasCountryConfirmed CasesFatal Cases202420252026202420252026Bolivia881420Brazil812004480Colombia2312525135113Guyana310010Peru194929190Ecuador0110080Venezuela03260192Total61346343014815Notes: Data for 2024 and 2025 correspond to all 53 epidemiological weeks, whereas data for 2026 cover epidemiological weeks 1–7 only. Source: Pan American Health Organization, 2026.72 Table 1Epidemiological Information on Confirmed and Fatal Cases of Yellow Fever in Countries Located in the Region of the AmericasCountryConfirmed CasesFatal Cases202420252026202420252026Bolivia881420Brazil812004480Colombia2312525135113Guyana310010Peru194929190Ecuador0110080Venezuela03260192Total61346343014815Notes: Data for 2024 and 2025 correspond to all 53 epidemiological weeks, whereas data for 2026 cover epidemiological weeks 1–7 only. Source: Pan American Health Organization, 2026.72 Epidemiological Information on Confirmed and Fatal Cases of Yellow Fever in Countries Located in the Region of the Americas Notes: Data for 2024 and 2025 correspond to all 53 epidemiological weeks, whereas data for 2026 cover epidemiological weeks 1–7 only. Source: Pan American Health Organization, 2026.72 This figure is directly linked to the record of epizootics during 2025 in the countries with the highest numbers of human cases and deaths: three epizootics in Bolivia, 124 yellow fever outbreaks among NHPs in Brazil, 82 epizootics in Colombia, and 90 in Venezuela. The role of NHPs as sentinels is invaluable, as it identifies viral circulation before human cases occur; this aids in georeferencing probable locations of human cases, identifying high-risk zones, anticipating preventive measures, and optimizing vaccination campaigns.72 In these countries, sylvatic transmission often predominates over urban transmission, mainly related to unvaccinated individuals working in the mining, agriculture, and extraction sectors. This pattern can be explained by the tropical climate of these regions and the agribusiness-oriented economy, which favors contact with wild mosquitoes. Although there is no susceptibility related to sex and age, in general, males in the economically active age range in rural areas are the most affected, reflecting the occupational profile of exposure.1,4,35,84 For example, in Brazil, two waves of sylvatic transmission that occurred between 2016 and 2018 totaled more than two thousand confirmed cases and about 700 deaths, constituting an epidemic. This episode stood out for its expansive pattern, as cases, previously restricted to the North region of the country, spread to the Southeast and South, reaching more than 130 municipalities, including densely populated areas, reflecting climate change and anthropogenic environmental impacts. During this period, 19 unvaccinated tourists were infected, and some contributed to the introduction of the yellow fever virus in seven countries, including France, the Netherlands, Germany, Romania, and Switzerland.2,4,17,18 Public Health Impacts Yellow fever has had a significant impact on global public health for over a century, exhibiting varying epidemiological intensities among countries over time. Currently, the WHO considers that 44 nations in Africa and Latin America have intermittent and sporadic cases of epizootic and human outbreaks of yellow fever, with 40 of these countries having an increased probability of outbreak risk.1–4,85 The official recognition of yellow fever as a disease of international importance dates back to 1951, when it was included in the first International Health Regulations (IHR) developed by the WHO.86 Following revisions to the document, the disease remains listed among those requiring mandatory notification to the WHO of confirmed and suspected cases in humans, related deaths, epizootics in non-human primates, and any risk of spread to other regions; notification must be made within 24 hours.87 Mandatory reporting is justified by the high potential of yellow fever to trigger large-scale outbreaks and the risk of international spread, especially through unvaccinated travelers, as occurred in Brazil in 2016–2018.1 This mechanism allows the WHO to issue global alerts, recommend vaccination campaigns and, when necessary, advise temporary travel restrictions; in order to prevent, detect and respond to outbreaks.3 In addition, in 2016, the WHO launched the Global Strategy to Eliminate Yellow Fever Epidemics (EYE), which addresses three strategic objectives: protecting at-risk populations, preventing cross-border transmission, and rapidly containing outbreaks. Actions vary according to the level of risk: in high-risk areas, immunization and coverage monitoring are prioritized; in moderate-risk areas, sentinel surveillance and rapid testing; and in areas with no current risk, strengthening health services and diagnostics.3,88 It is important to emphasize that the severity of the disease entails considerable additional financial costs to the health system related to response plans, surveillance, and preventive actions. This is especially true in severe cases due to prolonged hospitalization, ICU monitoring, and the need for high-cost procedures such as hemodialysis and high-volume plasmapheresis.1,8,46 Despite these impacts, the morbidity of post-cure AF tends to be low and transient, with symptoms persisting for weeks to a few months. Cases that progress to moderate and severe forms present a significantly higher risk of lethality and sequelae, especially when there are alterations in ALT parameters and renal excretion, with reports of late-onset recurrent hepatitis, pancreatitis, central nervous system manifestations, and severe progressive metabolic acidosis. This directly impacts public health, since the critical phase has a high lethality rate, ranging from 40 to 60% in South America and around 20% in Africa.1,8,44,89,90 Thus, it is observed that yellow fever exerts a considerable impact on public health, particularly in endemic countries that present high mortality rates, resulting in significant costs for the public health systems of these regions.2 This is evidenced mainly by the majority of emerging and underdeveloped countries in this situation, whose populations largely depend on state health assistance, which, in some cases, have limited sanitary infrastructure.35,91 Thus, it is observed that yellow fever exerts a considerable impact on public health, particularly in endemic countries that present high mortality rates, resulting in significant costs for the public health systems of these regions.2 This is evidenced mainly by the majority of emerging and underdeveloped countries in this situation, whose populations largely depend on state health assistance, which, in some cases, have limited sanitary infrastructure.35,91 In light of the foregoing, it is worth noting that yellow fever poses a persistent global challenge, placing a strain on the health systems of emerging countries due to the high fatality rate of severe forms of the disease and the high cost of complex treatments. Given the geographic expansion of vectors and tourism in tropical areas, disease containment depends on strict adherence to the International Health Regulations and on integrated strategies such as EYE. Thus, strengthening epidemiological surveillance and expanding vaccination coverage are essential to mitigate the risk of cross-border dissemination and the impacts on public health. The One Health Approach in the Context of Yellow Fever The term One Health refers to a transdisciplinary approach that recognizes the interconnectedness of human health, animal health, and environmental health as fundamental to addressing global health challenges. This model plays a key role in managing zoonotic diseases, climate change, food insecurity, and combating antimicrobial resistance.20,61,92–94 Although the essence of the One Health approach is not recent, with origins dating back to Ancient Greece, the term was introduced in the contemporary era in 1964 and underwent refinement in 2004, when it consolidated as an interdisciplinary perspective. The strengthening of this approach occurred in 2021 with the creation of the One Health High-Level Expert Panel (OHHLEP), focused on identifying and monitoring microorganisms with pandemic potential, as well as developing strategies for preventing and mitigating risks related to zoonoses. The panel aims to subsidize and support international institutions such as the WHO, the Food and Agriculture Organization of the United Nations (FAO), and the World Organisation for Animal Health (WOAH).20,94,95 The effectiveness of policies based on the One Health approach, at global and local levels, depends on the coordination between various sectors, such as social, political, economic, tourism, industrial, cultural, urban planning, and anthropological. This integration is essential, since zoonotic determinants extend beyond biological and environmental boundaries, requiring multi-sectoral and multi-institutional coordination to prevent their emergence, spread, and the resulting damage to the community.4,21,22 Based on this, in 2022, the One Health Joint Action Plan 2022–2026 (OH JPA) was established in a quadripartite manner by the WHO, FAO, WOAH, and the United Nations Environment Programme (UNEP). The plan includes six major lines of action, among them: reducing the risks of emerging and re-emerging zoonotic epidemics and pandemics; controlling and eliminating zoonotic diseases, neglected tropical diseases, and vector-borne diseases; and integrating the environment into the One Health concept.95 Additionally, it is noteworthy that many medical professionals are unaware of the One Health approach, making it necessary and fundamental to broaden its dissemination.23 It is important to emphasize that zoonoses constitute a challenge for global health, demanding integrated actions from sectors involving human, animal, and environmental health. From the perspective of the One Health approach, this problem requires global surveillance, control, and prevention measures, encompassing human surveillance, animal surveillance, and data sharing between the public health and veterinary sectors. To this end, communication must be improved to ensure the timely, safe, and accurate dissemination of information; furthermore, vaccination, when available, environmental monitoring, the commitment of individuals involved, and the improvement of biosafety and laboratory diagnostic practices are essential for the prevention and control of these diseases.96 Although yellow fever is preventable and subject to mandatory reporting, with a significant role played by human epidemiological surveillance and human health policies, it remains a relevant public health problem worldwide. This persistence is evidenced by the significant outbreaks recorded in recent decades, the substantial number of unvaccinated people who reside in or travel through endemic areas, and the recent expansion into new regions.2 Thus, it is observed that the One Health approach has important applicability and great potential for reducing cases of the disease.3 Non-human primates play a key role in this context, since YFV cannot be eliminated from these reservoirs due to their wide geographic distribution. Furthermore, it is not possible to precisely determine the core, timing, or location of a potential spillover into wild populations. However, outbreaks of this origin can be prevented through sentinel epidemiological surveillance of NHPs and human vaccination.14,15 These measures are essential to prevent both zoonosis and reverse zoonosis, requiring behavioral changes from field researchers, wildlife veterinarians, health professionals, park and zoo workers, forest extractors, government authorities, local residents, and tourists in endemic areas. Furthermore, they demand specific guidelines for conservation activities, pest control, wildlife population management, ecological consulting, animal rehabilitation in shelters, and the management of protected areas and natural environments.15 Vectors are another crucial determinant of yellow fever. In a retrospective analysis, it was found that among 87 mosquito species, approximately 30% were vectors favored by deforestation, including seven from the genus Aedes, such as A. africanus and A. albopictus, which are important in the intermediate transmission of yellow fever, especially in Africa.4,97 In South America, Haemagogus spp., a vector of sylvatic yellow fever, can be found on forest peripheries, increasing human exposure in deforested areas.42,43 Additionally, the presence of vectors in areas previously unsuitable for their reproduction exacerbates the transmission of yellow fever, which is further amplified by tourism, environmental exploitation, and climate change.98 Increased average temperatures and changes in precipitation patterns make previously unsuitable regions suitable for vector proliferation, while already favorable areas become even more conducive. It is estimated that, between 2030 and 2052, the global average temperature could rise by 1.5°C, favoring larval development, viral replication, and the expansion of vectors such as Aedes spp. and Haemagogus spp., while more intense rainfall increases reproduction.35 Gaythorpe et al projected different climate change scenarios (temperatures and precipitation) in Africa for the years 2050 and 2070, assessing the impacts on the transmissibility and viral load of yellow fever. The results indicated significant effects, with heterogeneous increases among countries in both variables analyzed, especially in Central and East Africa. The increase in the number of deaths was also estimated, suggesting a rise of 10 to 40%, depending on the scenario considered for 2070.99 This demonstrates the importance of the environmental dimension in formulating policies that reconcile preservation, sustainable development, and urban expansion.4 This relevance is accentuated in developing tropical countries, whose economies are heavily dependent on commodities and which, over the years, have shown a significant increase in deforestation rates for the exploitation of natural resources and urban expansion.100 In this context, the One Health approach proves essential in all dimensions of the yellow fever problem. Mensah et al proposed the use of this approach to reduce morbidity and mortality from yellow fever, as well as to control outbreaks in Uganda, a country that experiences at least one outbreak of the disease annually due to fragmented control and prevention systems. The authors suggest the creation of a national task force to coordinate yellow fever elimination actions, including a comprehensive surveillance system, strengthening laboratory capacity; regular vaccination campaigns; integration of vector management strategies; improved risk communication, with dissemination of knowledge, advice and perspectives for health professionals and individuals at risk of the disease; and identification of risk factors in human and non-human populations.61 Along the same lines, Nederlof et al correlated the One Health approach and yellow fever in non-human primates, highlighting its relevance to public health and the impact of changes in biodiversity, including climate change, habitat loss, human activities, and vector ecology. They also emphasized the importance of veterinarians and biologists in multidisciplinary teams, promoting data sharing and efficient communication in order to improve epidemiological understanding and the effectiveness of control measures.101 Thus, predicting, mitigating, and overcoming the challenges related to yellow fever, as well as seeking its eradication, require a comprehensive approach to this zoonosis, and the application of the One Health concept is a priority strategy for combating the disease.3,61,101 An illustrative representation of the One Health approach in the context of yellow fever is presented in Figure 1. Additionally, it is worth highlighting that the role of genomic surveillance in the context of yellow fever is fundamental to its control. The integration of genomic information with epidemiological, entomological, and epizootic data has broadened the understanding of viral circulation and strengthens surveillance strategies within the One Health approach. Figure 1Representation of the One Health approach in the context of yellow fever.The One Health approach connects human, animal and environmental health. ′HUMAN HEALTH′ includes: Surveillance, diagnosis, vaccination, education, outbreak management and monitoring travelers. ′ANIMAL HEALTH′ involves: Surveillance of non-human primates, investigation of deaths, lab diagnosis, rapid response and habitat conservation. ′ENVIRONMENTAL HEALTH′ covers: Vector surveillance, climate monitoring, risk area identification, vector control and ecosystem conservation. ′INTEGRATED ACTIONS′ focus on: Data sharing, integrated surveillance, joint risk analysis, coordinated responses and interdisciplinary research.A diagram of the One Health approach linking human, animal and environmental health. Representation of the One Health approach in the context of yellow fever. It is also worth noting that there are some challenges to implementing the One Health approach, mainly related to the lack of interinstitutional coordination and the operational limitations of surveillance and data sharing systems. Furthermore, having effective governance capacity is fundamental for the development and oversight of policies related to this topic. Finally, it is worth highlighting that yellow fever is a classic example of how human health does not exist in isolation and that its control depends on consolidating the One Health approach, expanding care to the animal and environmental spheres, which is fundamental to global public health. Only through continuous monitoring of ecosystems and protection of wildlife will it be possible to create an efficient sanitary barrier, anticipate outbreaks, and save human lives in a sustainable way. Conclusion Yellow fever is a centuries-old arboviral disease of worldwide scope, with a high mortality rate in cases that progress to the critical phase, making it a significant public health challenge, especially in tropical regions. Although spontaneous recovery occurs in mild forms, the management of severe cases is complex, as the initial manifestations resemble other zoonoses, making differential diagnosis difficult. Thus, accurate diagnosis and knowledge of risk areas are essential, since treatment is only supportive. It is worth noting that, given these factors, vaccination is the main preventive tool, along with epidemiological and sanitary surveillance. However, many countries lack the increased public investment needed to expand their capacity for yellow fever diagnosis, treatment, and prevention; reversing this situation is both necessary and urgent in order to mitigate the impacts caused by this zoonosis. The One Health approach is considered the foundational framework for yellow fever control, as the virus’s transmission dynamics occur at the inextricable intersection of ecosystems, wildlife, and human populations. In scenarios of ecological transition and anthropogenic pressure, habitat fragmentation and deforestation intensify contact between humans and the virus’s sylvatic cycle, amplifying the risk of zoonotic spillover. In this context, the effective mitigation of yellow fever cases and outbreaks depends directly on the synergy between epidemiological surveillance, predictive monitoring of non-human primates, and entomological surveillance, aligned with agile vaccination strategies in at-risk areas. These actions must be carried out through the lens of the One Health approach, ensuring holistic collaboration among the human, animal, and environmental health sectors, with coordinated and sustainable responses at various levels and across different spheres, including the development and implementation of applied public policies. Although recent scientific and biotechnological advances have improved disease control, historical bottlenecks in vaccine production, the geographical expansion of the virus into previously unaffected areas, and the impacts of climate change pose persistent challenges. Furthermore, many managers and health professionals remain unfamiliar with the principles of the One Health approach, which hinders its application in combating yellow fever. Thus, bridging these knowledge gaps and strengthening mitigation strategies are fundamental steps toward anticipating viral circulation and outbreaks, protecting vulnerable populations, and consolidating global health security.